Cargando…
Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
AIM: To investigate the cost-effectiveness of liraglutide as add-on to metformin vs. glimepiride or sitagliptin in patients with Type 2 diabetes uncontrolled with first-line metformin. METHODS: Data were sourced from a clinical trial comparing liraglutide vs. glimepiride, both in combination with me...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378710/ https://www.ncbi.nlm.nih.gov/pubmed/21883438 http://dx.doi.org/10.1111/j.1464-5491.2011.03429.x |
_version_ | 1782236082348228608 |
---|---|
author | Davies, M J Chubb, B D Smith, I C Valentine, W J |
author_facet | Davies, M J Chubb, B D Smith, I C Valentine, W J |
author_sort | Davies, M J |
collection | PubMed |
description | AIM: To investigate the cost-effectiveness of liraglutide as add-on to metformin vs. glimepiride or sitagliptin in patients with Type 2 diabetes uncontrolled with first-line metformin. METHODS: Data were sourced from a clinical trial comparing liraglutide vs. glimepiride, both in combination with metformin, and a clinical trial comparing liraglutide vs. sitagliptin, both as add-on to metformin. Only the subgroup of patients in whom liraglutide was added to metformin monotherapy was included in the cost–utility analysis. The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients’ lifetimes. Treatment effects were taken directly from the trials. Costs and outcomes were discounted at 3.5% per annum and costs were accounted from a third-party payer (UK National Health System) perspective. RESULTS: Treatment with liraglutide 1.2 and 1.8 mg resulted, respectively, in mean increases in quality-adjusted life expectancy of 0.32 ± 0.15 and 0.28 ± 0.14 quality-adjusted life years vs. glimepiride, and 0.19 ± 0.15 and 0.31 ± 0.15 quality-adjusted life years vs. sitagliptin, and was associated with higher costs of £3003 ± £678 and £4688 ± £639 vs. glimepiride, and £1842 ± £751 and £3224 ± £683 vs. sitagliptin, over a patient’s lifetime. Both liraglutide doses were cost-effective, with incremental cost-effectiveness ratios of £9449 and £16 501 per quality-adjusted life year gained vs. glimepiride, and £9851 and £10 465 per quality-adjusted life year gained vs. sitagliptin, respectively. CONCLUSIONS: Liraglutide, added to metformin monotherapy, is a cost-effective option for the treatment of Type 2 diabetes in a UK setting. |
format | Online Article Text |
id | pubmed-3378710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-33787102012-06-20 Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus Davies, M J Chubb, B D Smith, I C Valentine, W J Diabet Med Original Articles AIM: To investigate the cost-effectiveness of liraglutide as add-on to metformin vs. glimepiride or sitagliptin in patients with Type 2 diabetes uncontrolled with first-line metformin. METHODS: Data were sourced from a clinical trial comparing liraglutide vs. glimepiride, both in combination with metformin, and a clinical trial comparing liraglutide vs. sitagliptin, both as add-on to metformin. Only the subgroup of patients in whom liraglutide was added to metformin monotherapy was included in the cost–utility analysis. The CORE Diabetes Model was used to simulate outcomes and costs with liraglutide 1.2 and 1.8 mg vs. glimepiride and vs. sitagliptin over patients’ lifetimes. Treatment effects were taken directly from the trials. Costs and outcomes were discounted at 3.5% per annum and costs were accounted from a third-party payer (UK National Health System) perspective. RESULTS: Treatment with liraglutide 1.2 and 1.8 mg resulted, respectively, in mean increases in quality-adjusted life expectancy of 0.32 ± 0.15 and 0.28 ± 0.14 quality-adjusted life years vs. glimepiride, and 0.19 ± 0.15 and 0.31 ± 0.15 quality-adjusted life years vs. sitagliptin, and was associated with higher costs of £3003 ± £678 and £4688 ± £639 vs. glimepiride, and £1842 ± £751 and £3224 ± £683 vs. sitagliptin, over a patient’s lifetime. Both liraglutide doses were cost-effective, with incremental cost-effectiveness ratios of £9449 and £16 501 per quality-adjusted life year gained vs. glimepiride, and £9851 and £10 465 per quality-adjusted life year gained vs. sitagliptin, respectively. CONCLUSIONS: Liraglutide, added to metformin monotherapy, is a cost-effective option for the treatment of Type 2 diabetes in a UK setting. Blackwell Publishing Ltd 2012-03 /pmc/articles/PMC3378710/ /pubmed/21883438 http://dx.doi.org/10.1111/j.1464-5491.2011.03429.x Text en © 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
spellingShingle | Original Articles Davies, M J Chubb, B D Smith, I C Valentine, W J Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus |
title | Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus |
title_full | Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus |
title_fullStr | Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus |
title_full_unstemmed | Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus |
title_short | Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus |
title_sort | cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in type 2 diabetes mellitus |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378710/ https://www.ncbi.nlm.nih.gov/pubmed/21883438 http://dx.doi.org/10.1111/j.1464-5491.2011.03429.x |
work_keys_str_mv | AT daviesmj costutilityanalysisofliraglutidecomparedwithsulphonylureaorsitagliptinallasaddontometforminmonotherapyintype2diabetesmellitus AT chubbbd costutilityanalysisofliraglutidecomparedwithsulphonylureaorsitagliptinallasaddontometforminmonotherapyintype2diabetesmellitus AT smithic costutilityanalysisofliraglutidecomparedwithsulphonylureaorsitagliptinallasaddontometforminmonotherapyintype2diabetesmellitus AT valentinewj costutilityanalysisofliraglutidecomparedwithsulphonylureaorsitagliptinallasaddontometforminmonotherapyintype2diabetesmellitus |